169 related articles for article (PubMed ID: 25037863)
1. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV; Yang JC; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater SL; Orlov S; Tsai CM; Boyer M; Su WC; Bennouna J; Kato T; Gorbunova V; Lee KH; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M
J Clin Oncol; 2013 Sep; 31(27):3327-34. PubMed ID: 23816960
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
8. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Marshall J; Hwang J; Eskens FA; Burger H; Malik S; Uttenreuther-Fischer M; Stopfer P; Ould-Kaci M; Cohen RB; Lewis NL
Invest New Drugs; 2013 Apr; 31(2):399-408. PubMed ID: 23161335
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
Marshall J; Shapiro GI; Uttenreuther-Fischer M; Ould-Kaci M; Stopfer P; Gordon MS
Future Oncol; 2013 Feb; 9(2):271-81. PubMed ID: 23414476
[TBL] [Abstract][Full Text] [Related]
16. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
Gordon MS; Mendelson DS; Gross M; Uttenreuther-Fischer M; Ould-Kaci M; Zhao Y; Stopfer P; Agus DB
Invest New Drugs; 2013 Apr; 31(2):409-16. PubMed ID: 23242861
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
